|
1
|
O'Keefe SJ: Diet, microorganisms and their
metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol.
13:691–706. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kotelevets L, Chastre E, Desmaële D and
Couvreur P: Nanotechnologies for the treatment of colon cancer:
From old drugs to new hope. Int J Pharm. 514:24–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu T, Li Z, Gao CY and Cho CH: Mechanisms
of drug resistance in colon cancer and its therapeutic strategies.
World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takayama T, Miyanishi K, Hayashi T, Sato Y
and Niitsu Y: Colorectal cancer: Genetics of development and
metastasis. J Gastroenterol. 41:185–192. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
He C, Li L, Guan X, Xiong L and Miao X:
Mutant p53 gain of function and chemoresistance: The role of mutant
p53 in response to clinical chemotherapy. Chemotherapy. 62:43–53.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dart DA, Picksley SM, Cooper PA, Double JA
and Bibby MC: The role of p53 in the chemotherapeutic responses to
cisplatin, doxorubicin and 5-fluorouracil treatment. Int J Oncol.
24:115–125. 2004.PubMed/NCBI
|
|
8
|
Ravi R, Jain AJ, Schulick RD, Pham V,
Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, et
al: Elimination of hepatic metastases of colon cancer cells via
p53-independent cross-talk between irinotecan and Apo2
ligand/TRAIL. Cancer Res. 64:9105–9114. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arango D, Wilson AJ, Shi Q, Corner GA,
Arañes MJ, Nicholas C, Lesser M, Mariadason JM and Augenlicht LH:
Molecular mechanisms of action and prediction of response to
oxaliplatin in colorectal cancer cells. Br J Cancer. 91:1931–1946.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rogosnitzky M and Danks R: Therapeutic
potential of the biscoclaurine alkaloid, cepharanthine, for a range
of clinical conditions. Pharmacol Rep. 63:337–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara
M, Kato M, Akhand AA, Hayakawa A, Takeuchi K, Hossain K, et al:
Cepharanthine activates caspases and induces apoptosis in Jurkat
and K562 human leukemia cell lines. J Cell Biochem. 82:200–214.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu J, Suzuki H, Akhand AA, Zhou YW,
Hossain K and Nakashima I: Modes of activation of mitogen-activated
protein kinases and their roles in cepharanthine-induced apoptosis
in human leukemia cells. Cell Signal. 14:509–515. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harada K, Supriatno, Yamamoto S, Kawaguchi
S, Yoshida H and Sato M: Cepharanthine exerts antitumor activity on
oral squamous cell carcinoma cell lines by induction of p27Kip1.
Anticancer Res. 23B:1441–1448. 2003.
|
|
14
|
Biswas KK, Tancharoen S, Sarker KP,
Kawahara K, Hashiguchi T and Maruyama I: Cepharanthine triggers
apoptosis in a human hepatocellular carcinoma cell line (HuH-7)
through the activation of JNK1/2 and the downregulation of Akt.
FEBS Lett. 580:703–710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kikukawa Y, Okuno Y, Tatetsu H, Nakamura
M, Harada N, Ueno S, Kamizaki Y, Mitsuya H and Hata H: Induction of
cell cycle arrest and apoptosis in myeloma cells by cepharanthine,
a biscoclaurine alkaloid. Int J Oncol. 33:807–814. 2008.PubMed/NCBI
|
|
16
|
Seubwai W, Vaeteewoottacharn K, Hiyoshi M,
Suzu S, Puapairoj A, Wongkham C, Okada S and Wongkham S:
Cepharanthine exerts antitumor activity on cholangiocarcinoma by
inhibiting NF-kappaB. Cancer Sci. 101:1590–1595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uthaisar K, Seubwai W, Srikoon P,
Vaeteewoottacharn K, Sawanyawisuth K, Okada S and Wongkham S:
Cepharanthine suppresses metastatic potential of human
cholangiocarcinoma cell lines. Asian Pac J Cancer Prev. 13
Suppl:149–154. 2012.PubMed/NCBI
|
|
18
|
Chen Z, Huang C, Yang YL, Ding Y, Ou-Yang
HQ, Zhang YY and Xu M: Inhibition of the STAT3 signaling pathway is
involved in the antitumor activity of cepharanthine in SaOS2 cells.
Acta Pharmacol Sin. 33:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang ZH, Li YJ, Chen Z, Wang JJ and Zhu
LH: Inhibition of signal transducer and activator of transcription
3 and cyclooxygenase-2 is involved in radiosensitization of
cepharanthine in HeLa cells. Int J Gynecol Cancer. 23:608–614.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu G, Wu D, Liang X, Yue H and Cui Y:
Mechanisms and in vitro effects of cepharanthine hydrochloride:
Classification analysis of the drug-induced
differentially-expressed genes of human nasopharyngeal carcinoma
cells. Oncol Rep. 34:2002–2010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hua P, Sun M, Zhang G, Zhang Y, Tian X, Li
X, Cui R and Zhang X: Cepharanthine induces apoptosis through
reactive oxygen species and mitochondrial dysfunction in human
non-small-cell lung cancer cells. Biochem Biophys Res Commun.
460:136–142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ebina T, Ishikawa K and Murata K:
Antitumor effect of Cepharanthin in the double grafted tumor
system. Gan To Kagaku Ryoho. 17:1165–1171. 1990.(In Japanese).
PubMed/NCBI
|
|
23
|
Takahashi-Makise N, Suzu S, Hiyoshi M,
Ohsugi T, Katano H, Umezawa K and Okada S: Biscoclaurine alkaloid
cepharanthine inhibits the growth of primary effusion lymphoma in
vitro and in vivo and induces apoptosis via suppression of the
NF-kappaB pathway. Int J Cancer. 125:1464–1472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harada K, Ferdous T, Itashiki Y, Takii M,
Mano T, Mori Y and Ueyama Y: Cepharanthine inhibits angiogenesis
and tumorigenicity of human oral squamous cell carcinoma cells by
suppressing expression of vascular endothelial growth factor and
interleukin-8. Int J Oncol. 35:1025–1035. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harada K, Bando T, Yoshida H and Sato M:
Characteristics of antitumour activity of cepharanthin against a
human adenosquamous cell carcinoma cell line. Oral Oncol.
37:643–651. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bun SS, Laget M, Chea A, Bun H, Ollivier E
and Elias R: Cytotoxic activity of alkaloids isolated from
Stephania rotunda [corrected]. Phytother Res. 23:587–590. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brunelle JK and Letai A: Control of
mitochondrial apoptosis by the Bcl-2 family. J Cell Sci.
122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fang J, Nakamura H and Iyer AK:
Tumor-targeted induction of oxystress for cancer therapy. J Drug
Target. 15:475–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giaccone G and Pinedo HM: Drug Resistance.
Oncologist. 1:82–87. 1996.PubMed/NCBI
|
|
30
|
Vazquez A, Bond EE, Levine AJ and Bond GL:
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat
Rev Drug Discov. 7:979–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hientz K, Mohr A, Bhakta-Guha D and
Efferth T: The role of p53 in cancer drug resistance and targeted
chemotherapy. Oncotarget. 8:8921–8946. 2017.PubMed/NCBI
|
|
32
|
Pan MH, Gao JH, Lai CS, Wang YJ, Chen WM,
Lo CY, Wang M, Dushenkov S and Ho CT: Antitumor activity of
3,5,4′-trimethoxystilbene in COLO 205 cells and xenografts in SCID
mice. Mol Carcinog. 47:184–196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng TC, Lai CS, Chung MC, Kalyanam N,
Majeed M, Ho CT, Ho YS and Pan MH: Potent anti-cancer effect of
3′-hydroxypterostilbene in human colon xenograft tumors. PLoS One.
9:e1118142014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ko CH, Shen SC, Lee TJ and Chen YC:
Myricetin inhibits matrix metalloproteinase 2 protein expression
and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther.
4:281–290. 2005.PubMed/NCBI
|
|
35
|
Wyllie F, Haughton M, Bartek J, Rowson J
and Wynford-Thomas D: Mutant p53 can delay growth arrest and loss
of CDK2 activity in senescing human fibroblasts without reducing
p21(WAF1) expression. Exp Cell Res. 285:236–242. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shin SY, Ahn S, Koh D and Lim Y:
p53-dependent and -independent mechanisms are involved in
(E)-1-(2-hydroxyphenyl)-3-(2-methoxynaphthalen-1-yl)prop-2-en-1-one
(HMP)-induced apoptosis in HCT116 colon cancer cells. Biochem
Biophys Res Commun. 479:913–919. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mukhtar E, Adhami VM, Khan N and Mukhtar
H: Apoptosis and autophagy induction as mechanism of cancer
prevention by naturally occurring dietary agents. Curr Drug
Targets. 13:1831–1841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeong JH, Kang SS, Park KK, Chang HW,
Magae J and Chang YC: p53-independent induction of G1 arrest and
p21Waf1/Cip1 expression by ascofuranone, an isoprenoid antibiotic,
through downregulation of c-Myc. Mol Cancer Ther. 9:2102–2113.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aguero MF, Venero M, Brown DM, Smulson ME
and Espinoza LA: Phenoxodiol inhibits growth of metastatic prostate
cancer cells. Prostate. 70:1211–1221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jia L, Li H and Sun Y: Induction of
p21-dependent senescence by an NAE inhibitor, MLN4924, as a
mechanism of growth suppression. Neoplasia. 13:561–569. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Masgras I, Carrera S, de Verdier PJ,
Brennan P, Majid A, Makhtar W, Tulchinsky E, Jones GD, Roninson IB
and Macip S: Reactive oxygen species and mitochondrial sensitivity
to oxidative stress determine induction of cancer cell death by
p21. J Biol Chem. 287:9845–9854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fitzgerald AL, Osman AA, Xie TX, Patel A,
Skinner H, Sandulache V and Myers JN: Reactive oxygen species and
p21Waf1/Cip1 are both essential for p53-mediated senescence of head
and neck cancer cells. Cell Death Dis. 6:e16782015. View Article : Google Scholar : PubMed/NCBI
|
